A fully connected imaging ecosystem – centralized access, integrated workflows, and AI-powered imaging to accelerate diagnosis and elevate care
Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence
Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of Directors
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February...
/Idexx%20Laboratories%2C%20Inc_%20phone%20and%20chart%20-by%20IgorGolovniov%20via%20Shutterstock.jpg)
IDEXX Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings increase.
/Idexx%20Laboratories%2C%20Inc_%20outside%20lab-by%20Sundry%20Photography%20via%20iStock.jpg)
Although IDEXX Laboratories has outperformed the healthcare sector over the past year, analysts remain cautiously optimistic about the stock’s prospects.
/Danaher%20Corp_%20logo%20on%20vial-by%20Melnilov%20Dmitriy%20via%20Shutterstock.jpg)
Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.
/Thermo%20Fisher%20Scientific%20Inc_%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
Thermo Fisher Scientific has outperformed the broader healthcare sector over the past year, and analysts continue to hold a strongly bullish view on its growth prospects.
IDEXX Laboratories has considerably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
December S&P 500 E-Mini futures (ESZ25) are down -1.01%, and December Nasdaq 100 E-Mini futures (NQZ25) are down -1.31% this morning as quarterly results from AI bellwether Palantir failed to impress investors...